Canopus BioPharma Inc. announces positive results from an In-Vitro live Ebola Virus study

LOS ANGELES, Dec. 19, 2014 (Canada NewsWire via COMTEX) Canopus BioPharma Inc. (OTC Pink: CBIA) today announces that it has completed crucial research in confirming efficacy of a prescription drug: CB008 for Ebola Virus inhibition. Laboratories at the Texas Biomedical Research Institute in San Antonio Texas have demonstrated complete in-vitro inhibition of the live Ebola Virus strain Zaire at concentrations of CB008 that are achievable by oral administration. CB008 is only one of a family of prescription drugs which has been demonstrated by Canopus BioPharma to have potential in preventing Hemorrhagic syndrome and inhibiting Ebola Viral replication. CB008 is an in-house codename for a well-established prescription drug first approved by the FDA in the early 1980 s for other medical indications. CB008 is an effective, safe treatment for Ebola Virus. Canopus BioPharma has signed a confidential agreement with a major pharmaceutical company who are reviewing the results and the possibili
http://bit.ly/1GZZZ1A